about
Review: Gout: A Roadmap to Approaches for Improving Global OutcomesCrystal arthritides - gout and calcium pyrophosphate arthritis : Part 1: Epidemiology and pathophysiology.Allopurinol and the risk of atrial fibrillation in the elderly: a study using Medicare data.Serum uric acid level and its association with cardiometabolic risk factors in prediabetic subjects.Association between allopurinol and mortality among Japanese hemodialysis patients: results from the DOPPS.Interaction of inflammation, hyperuricemia, and the prevalence of hypertension among adults free of metabolic syndrome: NHANES 2009-2010.Allopurinol initiation and all-cause mortality in the general population.Gout and subsequent increased risk of cardiovascular mortality in non-diabetics aged 50 and above: a population-based cohort study in Taiwan.An old disease with new insights: Update on diagnosis and treatment of gout.Impact of allopurinol use on urate concentration and cardiovascular outcomeHyperuricemia and coronary heart disease: a systematic review and meta-analysis.The epidemiology of uric acid and fructose.Effect of Urate-Lowering Therapy on All-Cause and Cardiovascular Mortality in Hyperuricemic Patients without Gout: A Case-Matched Cohort StudyRole of Community Pharmacies for the Detection of Potentially Inappropriate Xanthine Oxidase Inhibitor PrescriptionsColchicine use is associated with decreased prevalence of myocardial infarction in patients with gout.Multicentre, prospective, randomised, open-label, blinded end point trial of the efficacy of allopurinol therapy in improving cardiovascular outcomes in patients with ischaemic heart disease: protocol of the ALL-HEART study.Allopurinol reduces the risk of myocardial infarction (MI) in the elderly: a study of Medicare claims.The challenges of gout management in the elderly.Xanthine oxidase inhibition for the treatment of cardiovascular disease: a systematic review and meta-analysis.Gout and organ transplantation.Hyperuricemia and renal risk.Impact of allopurinol on risk of myocardial infarction.Gout: An old disease in new perspective - A review.Longitudinal Association Between Serum Uric Acid and Arterial Stiffness: Results From the Baltimore Longitudinal Study of Aging.Effect of allopurinol on all-cause mortality in adults with incident gout: propensity score-matched landmark analysis.Elevated serum uric acid in nondiabetic people mark pro-inflammatory state and HDL dysfunction and independently predicts coronary disease.The role of urate-lowering treatment on cardiovascular and renal disease: evidence from CARES, FAST, ALL-HEART, and FEATHER studies.Tophaceous gout and high level of hyperuricaemia are both associated with increased risk of mortality in patients with gout.A two-stage approach to the treatment of hyperuricemia in gout: The “dirty dish” hypothesisInappropriate prescription of allopurinol and febuxostat and risk of adverse events in the elderly: results from the REPOSI registry
P2860
Q28076018-50283606-0844-4176-B085-7DCD34B822DFQ30235586-2596CAC8-8226-4B67-8A09-A9AEEDC27528Q31095161-54492321-48C7-4D60-A970-F0454F2D4FFFQ33771402-4733BD4A-D104-471F-8750-E20AE3BB411DQ34100586-DE520117-9FD5-4E32-BCAE-A8BE6660390FQ34297252-26F26224-864D-4DC0-BA1C-9F32AA73EA9CQ34466066-FE5B15BE-4CB9-49B6-9596-1C7AA0DE1418Q34484081-0E1C2CB5-F0C3-4994-9DAE-1F9A5B35377AQ34542091-BA412D1F-780D-4644-BA0C-F7A8C479B6EFQ34830158-5688FAC4-939F-40E9-8D8E-334467198A9AQ35166411-F05962A0-F70B-4C53-88F2-D9EAF280CAA5Q35393502-8ACB8E95-E155-4E18-8408-0BA480D8A752Q35873062-A1D15269-88FC-42D4-BE34-397AF8D01A38Q36942867-C3142BD7-47AD-4010-A734-C59382DC5F7BQ37070180-619A3904-7481-4FAC-ABFF-EF33A8133C44Q37251800-7F0AE6B9-8B46-49A1-85E4-83898B35B470Q37274458-964233A4-4D04-4E2F-A759-EF460F5FCFD4Q37910891-91587072-7539-46FA-B4BC-4092172BF684Q37958283-90C01E6B-0237-4A3C-A52A-385BD7CC6876Q37976996-6CF0D7AD-181C-424B-857E-15FEE2CF40EDQ38183774-0B1C3754-13FD-4BE5-AA96-6FF655585D9EQ39033643-A0D1CB01-51E2-4B2D-94BB-1CFEA11D63C8Q40106739-AF6EC20B-E171-43A9-B0BC-DCB6658FF3A1Q40428192-D8DADDA5-3EAA-464E-92AC-6E5E456242DEQ40742040-9BBA8E92-04D3-44F6-BB97-C02D414F3F98Q47808087-16603EC7-00D7-4E3C-AFD2-DBDBDB587FCEQ49793137-66B6E880-6741-4679-AB59-8C564132DD46Q51203256-8AEB06C8-0F72-4EC3-B005-48B03B6A0FD4Q56966774-36050E49-C663-408E-AABB-07AE5D352841Q58419002-9928DC87-C371-443E-B1A7-AE902FA77986
P2860
description
2009 nî lūn-bûn
@nan
2009年の論文
@ja
2009年論文
@yue
2009年論文
@zh-hant
2009年論文
@zh-hk
2009年論文
@zh-mo
2009年論文
@zh-tw
2009年论文
@wuu
2009年论文
@zh
2009年论文
@zh-cn
name
Allopurinol and mortality in hyperuricaemic patients.
@ast
Allopurinol and mortality in hyperuricaemic patients.
@en
type
label
Allopurinol and mortality in hyperuricaemic patients.
@ast
Allopurinol and mortality in hyperuricaemic patients.
@en
prefLabel
Allopurinol and mortality in hyperuricaemic patients.
@ast
Allopurinol and mortality in hyperuricaemic patients.
@en
P2093
P2860
P356
P1433
P1476
Allopurinol and mortality in hyperuricaemic patients.
@en
P2093
Andrew J Luk
Elya E Moore
Gregory P Levin
Hyon K Choi
Xiao-Hua Zhou
P2860
P304
P356
10.1093/RHEUMATOLOGY/KEP069
P577
2009-05-15T00:00:00Z